Semaglutide — dosage, half-life & reference guide

Metabolic & GLP-1 peptide · also known as Ozempic, Wegovy, Rybelsus

A GLP-1 receptor agonist that mimics a gut hormone your body releases after eating. Semaglutide reduces appetite, slows stomach emptying, and quiets the constant background thoughts about food ("food noise"). FDA-approved for both type 2 diabetes and weight management, with extensive clinical trial data showing 15%+ body weight loss over a year.

Commonly-researched dose ranges

Semaglutide is commonly researched at 0.25–2.4 mg, weekly subq, by SubQ injection. These are reference ranges from the literature and community use, not a prescription.

Half-life

Estimated half-life: ~1 week. See how it accumulates in the half-life calculator.

Safety & interactions

Across the STEP and SELECT programs, semaglutide's adverse events are predominantly mild-to-moderate transient gastrointestinal effects; in SELECT, discontinuation for adverse events was higher than placebo (16.6% vs 8.2%), driven by GI events, while overall serious adverse events were actually lower than placebo. Gallbladder/biliary events (cholelithiasis) were more frequent than placebo (~2.8%), and acute pancreatitis was rare with no notable signal vs placebo across STEP 1-5. It shares the GLP-1-class rodent thyroid C-cell warning. These are trial/label findings — discuss with your clinician.

Open the full Semaglutide guide (needs JavaScript). PepVault is a private research and tracking tool, not medical advice.